As part of its health threat plan activated to fight COVID-19, the Agency has finalised and published the composition and objectives of its COVID-19 EMA pandemic Task Force (COVID-ETF),which assists Member States and the European Commission in dealing with development, authorisation and safety monitoring of therapeutics and vaccines intended for treatment or prevention of COVID-19.
The main purpose of the COVID-ETF is to draw on the expertise of the European medicines regulatory network and ensure a fast and coordinated response to the COVID-19 pandemic. The task force is accountable to EMA’s human medicines committee (CHMP) for all its activities. Strict rules are in place to assure the independence of all members.